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Abstract. Mitochondrial and metabolic dysfunction have been linked to Alzheimer’s disease for some time. Key questions re-
garding this association concern the nature and mechanisms of mitochondrial dysfunction, and whether such changes in metabolic
properties are pathogenic or secondary, with respect to neuronal degeneration. In terms of mitochondria and Alzheimer’s, altered
function could reflect intrinsic properties of this organelle, potentially due to mutations in mitochondrial DNA, or extrinsic changes
secondary to signal transduction mechanisms activated in the cytosol. This review presents data relevant to these questions,
and considers the implication of recent findings demonstrating the presence of amyloid-β peptide in mitochondria, as well as
intra-mitochondrial molecular targets with which it can interact. Regardless of the underlying mechanism(s), it is likely that
mitochondrial dysfunction contributes to oxidant stress which is commonly observed in brains of patients with Alzheimer’s and
transgenic models of Alzheimer’s-like pathology.
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1. Introduction
Changes in brain energy metabolism are fundamen-
tal to the biology of Alzheimer’s Disease (AD), sug-
gesting the possibility that amyloid-β peptide (Aβ) im-
pacts on pathways important for metabolic homeosta-
sis. Several key findings link mitochondria to Aβ-
induced cellular perturbation. First, intact/functional
mitochondria are required for Aβ-induced cytotoxi-
city [1]. Second, mitochondrial dysfunction, espe-
cially at the level of cytochrome c oxidase/complex IV
(COX), is a consistent finding in AD-affected tissues,
as well as in platelet mitochondria derived from AD
patients [2–6]. Third, consistent with metabolic stress,
gene expression profiling in a transgenic model of AD
(Tg 2576 mice) has shown early upregulation of genes
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related to mitochondrial energy metabolism in animals
as young as 2 months of age [7]. Such mitochondrial
dysfunction has the capacity to produce reactive oxy-
gen species (ROS), which can impact the processing
of amyloid-β precursor protein (AβPP), intracellular
accumulation of Aβ and cellular energetics, such as
the level of ATP. Finally, certain mutations in mito-
chondrial (mt) DNA have been selectively identified in
the control region from patients with AD which reduce
transcription and are likely to decrease oxidative phos-
phorylation in the brain [8]. These results suggest a
close link between AD and mitochondrial properties.
This conclusion is further underscored by recent ob-
servations showing that Aβ can accumulate in mito-
chondria [9] where it engages specific molecular targets
such as Aβ binding alcohol deydrogenase (ABAD) and
HtrA2/Omi [10,11].
The above observations provide the background for
this review, which presents data supporting links be-
tween mitochondrial dysfunction and the pathogene-
sis/progression of AD.
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2. Mitochondrial dysfunction in AD
Mitochondria contribute to neuronal homeostasis on
many levels, including maintenance of the cellular en-
ergy charge, intracellular calcium levels [12], regula-
tion of programmedcell death [13] and limiting oxidant
stress. Electrons continuously flow through the elec-
tron transport chain, as reducing equivalents extracted
from nutrients generate the proton motive force essen-
tial for aerobic generation of ATP. Morphological al-
terations in mitochondria have been noted in AD brain,
though these changes are limited to vulnerable neurons
in the hippocampus and neocortex [14,15]. Labeling of
neurons by in situ hybridization with oligonucleotide
probes for mtDNA demonstrated an increased signal in
AD, but this was apparently due to accumulation of mi-
tochondrial markers in the cytoplasm associated with
autophagosomal degradation of mitochondria [14]. In
vulnerable portions of AD brain, morphometry showed
a decrease in the area of intact mitochondria. Other
investigators [15] have noted morphologic changes in
AD mitochondria, including changes in cristae, accu-
mulated material and decreased size, compared with
controls.
Even prior to the above alterations in mitochondrial
morphology, investigators have suspected links be-
tween dysfunctional mitochondrial energetics/electron
transport chain and AD [16]. Several lines of evidence
have provided support for this hypothesis.
1) Imaging studies using positron emission tomog-
raphy (PET) have shown hypometabolism, espe-
cially in the temporoparietal cortex of patients
with AD [17–21] at an early clinical stage of the
disease.
2) Experiments have also been performed using the
cytoplasmic hybrid (or cybrid) technique [22] in
which mitochondrial DNA/mitochondria are in-
troduced into a host cell which has been de-
pleted of mitochondria. Platelet mitochondria,
from AD patients or age-matched controls, have
been transferred into neuronal-like replicating
(neuroblastoma; SH-SY5Y) host cells devoid of
mitochondria. These studies have provided in-
sights into a link between a defect in the elec-
tron transport chain, oxidant stress and genera-
tion of Aβ. Cybrids made with AD mitochon-
dria displayed decreased cytochrome oxidase ac-
tivity and increased evidence of reactive oxygen
species (ROS). In parallel, such decreased mito-
chondrial function was associated with increased
secretion of Aβ (using host neuronal-related cells
and platelets from AD patients) [23,24], and vul-
nerability to the effects of Aβ, including an exag-
gerated decrease in the mitochondrial membrane
potential, release of cytochrome c and activated
caspase c resulting in cell death [24]. These data
suggest that mitochondrial DNA contains infor-
mation leading to decreased cytochrome c oxi-
dase activity which could be a fundamental defect
resulting in a cycle of increasing oxidant stress
and generation of Aβ (see below). The observa-
tion that nitric oxide (NO) can be induced in set-
tings of cell stress, and that NO also suppresses
cytochrome c oxidase activity, provides another
mechanism reinforcing this pathway [25,26].
3) The activity of mitochondrial enzymes involved
in the Krebs cycle and electron transfer chain
components has also been analyzed in AD. Ear-
lier studies on autoptic human brain from AD pa-
tients have demonstrated decreases in pyruvate
dehydrogenase complex activity [27], as well as
α-ketoglutarate dehydrogenase [28,29]. How-
ever, the most consistent reported abnormality in
mitochondrial enzyme activity is in cytochrome
c oxidase [2–6,30].
3. Oxidant stress in AD
AD is closely associated with oxidant stress on many
levels. As the principal source of reactive oxygen
species (ROS) in cells, mitochondria are a key po-
tential generator of oxidants. In addition, membrane-
associated NADPH oxidase, whose activation can be
triggered following engagement of cell surface recep-
tors [31–34] by Aβ, has the potential to produce ROS.
Mitochondrial DNA is especially susceptible to ox-
idative damage in view of the limited repair mecha-
nisms, lack of histones and physical contiguity to the
source of ROS [35,36]. For example, 8-hydroxy-2’-
deoxyguanosine, an oxidized base, has proven to be a
useful marker of oxidant stress [37]. Levels of several
oxidized bases in AD brain were found to be higher in
frontal, parietal and temporal lobes compared to age-
matched controls [38]. MtDNA displayed about 10-
fold greater levels of oxidized bases than nuclear DNA.
In addition, protein and lipid oxidation has been noted
in AD [39,40]. Proteins and lipids damaged by oxi-
dant stress, which have been demonstrated in AD, may
display altered function, and products of lipid oxida-
tion, such as the aldehyde 4-hydroxy-2-nonenal, can
have toxic effects. Oxidant stress is also manifested in
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AD-affected tissue as displayed by activation of NF-κB
and induction of genes such as heme oxygenase type
1 [41–43], though multiple pathways can trigger these
mechanisms.
Another level at which oxidant stress may be rel-
evant to the pathogenesis of AD involves genera-
tion of Aβ and induction of BACE-1 [44,45]. Stud-
ies in Down’s syndrome brains/neurons have shown
that cortical neurons from fetal Down’s Syndrome un-
dergo programmed cell death in culture, compared
with controls. Oxygen-free radical scavengers had
the capacity to prevent such apoptosis [46]. Further
study of astrocyte and neuronal cultures from fetal
Down’s syndrome brain displayed changes in process-
ing of AβPP which resulted in intracellular accumu-
lation of Aβ42. Inhibition of mitochondrial func-
tion using an uncoupling agent (carbonyl cyanide m-
chlorophenylhydrazone, CCCP) in astrocyte cultures
reproduced changes in AβPP processing observed in
Down’s Syndrome brain [47]. There are additional
links between intracellular production of Aβ and oxi-
dant stress. In studies with NT2 cells, incubation with
4-hydroxy-2,3-nonenal resulted in elevated levels of in-
tracellular Aβ [48]. These data, though fragmentary
and principally in cell culture, suggest linkage between
generation of intracellular Aβ and oxidant stress.
Generation of oxidants in response to Aβ can occur
by multiple mechanisms. One mechanism particularly
relevant in the setting of extracellular Aβ is engage-
ment of cellular receptors. Aβ binding to RAGE re-
sults in the generation of ROS due, at least initially,
to activation of NADPH oxidase [31,49]. At later
times, probably, ROS are produced by mitochondrial-
dependent pathways as well [50]. This mechanism may
be especially relevant in astrocytes/microglia, which
display NADPH oxidase-like enzymatic activity [32].
These data suggest pathways by which ROS in as-
trocytes/microglia might directly and/or indirectly (via
mediators/cytokines) impact on neurons.
Mitochondrial dysfunction is an important source of
ROS. When there is a distal blockade in mitochondrial
function, as at complex IV, then there is a tendency for
electrons to leak to acceptors more proximally and to
generate ROS, rather than water. This is particularly
relevant in AD where the most consistent defect in the
electron transport chain is at complex IV [2–6].
4. Amyloid Precursor Protein (AβPP) and
γ-secretase are present in mitochondria
Recent studies have demonstrated that both AβPP
and γ-secretase are present in mitochondria, suggest-
ing the possibility that Aβ might be generated in this
cellular compartment. Anandatheerthavarada and col-
leagues [51] have shown that AβPP has an amino-
terminal signal that targets it to mitochondria, in ad-
dition to endoplasmic reticulum (this finding has only
been shown in this paper). This was similar to what
these authors noted previously with P450A1, P4502B1
and P4502E1 proteins, based on the similarity of amino
terminal chimeric signals [52]. In particular, positively
charged residues 40, 44 and 51 in AβPP were essen-
tial for mitochondrial targeting. The orientation of
AβPP in mitochondria, based on cross-linking studies,
seemed to be with the molecule’s amino terminus in a
transmembrane orientation at the inner mitochondrial
membrane and in contact with mitochondrial translo-
case proteins. The C-terminus (about 73 kDa) was fac-
ing the cytosol. Because of the presence of the acidic
domain of AβPP (residues 220–290), the molecule is
subject to translocation arrest, whereby AβPP becomes
trapped in the mitochondrial membrane due to incom-
plete translocation. Thus, AβPP accumulates in the
mitochondrial membrane, and this appears to have con-
sequences for mitochondrial function, including de-
creased cytochrome c oxidase activity, diminished lev-
els of cellular ATP and decreased mitochondrial trans-
membrane potential, based on in vitro studies.
As a counterpart to these studies on AβPP in mito-
chondria, recent experiments have shown the presence
of γ-secretase in mitochondria. The γ-secretase com-
plex consists of the catalytic core,due to presenilins 1 or
2, as well as three other proteins; nicastrin, APH-1 (an-
terior pharynx-defective phenotype) and PEN-2 (PS-
enhancer) [53]. Functional complexes containing pre-
senilin have been demonstrated in multiple intracellular
compartments, including endolysosomes, the plasma
membrane, ER-Golgi boundary, trans-Golgi network,
lipid rafts of post-Golgi/endosomemembranes, and mi-
tochondria [54–57]. In the context of mitochondria,
γ-secretase activity appears to be associated with the
mitochondrial inner membrane where immunolocal-
ization studies have identified presenilin 1 and nicas-
trin [57]. It should be noted that in view of the orien-
tation of AβPP in mitochondria, with the C-terminus
exposed to the cytoplasm, it would be difficult for γ-
secretase at the inner membrane to appropriately inter-
act with its cleavage sites. Furthermore, the functional
significance of such secretase activity is not at all clear
at the present time.
Furthermore, in order for AβPP to be a substrate for
γ-secretase, it is first cleaved by BACE-1 (β-site AβPP
cleaving enzyme). It would appear that endosomes and
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plasma membrane are the principal sites of BACE-1
cleavage of AβPP [58]. No BACE-1 activity has been
detected in mitochondria. Thus, based on the lack of
BACE-1 in mitochondria and the orientation of AβPP
in mitochondrial membranes, it appears unlikely that
Aβ is generated in mitochondria.
5. Aβ is present in mitochondria
Although Aβ was initially thought to be generated
principally at the cell membrane and released extracel-
lularly, the existence of intracellular Aβ is now well-
established [59–69]. Sites of intracellular Aβ genera-
tion include the endoplasmic reticulum/Golgi compart-
ment as well as endolysosomes [70–75], and intracel-
lular accumulation occurs in these same portions of the
cell as well as in multivesicular bodies [61,64,76]. Be-
cause of links between mitochondrial dysfunction and
AD, we considered the possibility that Aβ might have
a direct effect on mitochondria, potentially by entering
the organelle. This led us to perform experiments in
transgenic mice (Tg) overexpressingmutant AβPP [77]
and AD brain patient samples [9]. In order to ensure
mitochondrial integrity, postmortem AD samples and
nondemented control brains were harvested with a time
delay of less than 3.5 hours. Biochemical studies on mi-
tochondria purified from cerebral cortices of Tg mAPP
mice and AD brains demonstrated the presence of Aβ
in highly purified fractions. Importantly, protease treat-
ment of mitochondria, to release Aβ adsorbed to the
organelle’s surface, did not remove immunoreactive
Aβ, indicating the presence of amyloid-β peptide in a
membrane enclosed compartment.
Morphologic studies were also performed to assess
the possible localization of Aβ to mitochondria [9].
Using confocal microscopy, Aβ42 was shown to colo-
calize with HSP60, the latter a marker of mitochondrial
matrix. Neurons in the cortex (Fig. 1A) and hippocam-
pus (Fig. 1B) displayed an overlapping distribution of
Aβ42 and HSP60 antigens. About 40% and 20% of
the area occupied by mitochondria could be colocal-
ized with Aβ in the cerebral cortex and hippocampus,
respectively. In contrast, nonTg littermates showed un-
detectable Aβ42 antigen (Fig. 1C). When comparable
studies were performed in AD brain, colocalization of
Aβ was also observed in mitochondria (about 40% and
70% of the area occupied by mitochondria costained
with antibody to Aβ in temporal lobe and hippocampus,
respectively). In human nondemented control samples,
accumulation of Aβ was seen, but to a much lesser
extent than in AD.
The time course of accumulation of Aβ in mitochon-
dria in brains of Tg AβPP mice was assessed in animals
from 4–24 months of age [9]. The most rapid phase of
Aβ accumulation appeared to be from 8–12 months of
age, for both Aβ42 and Aβ40 (Fig. 2A–B). However,
levels of Aβ42 were considerably higher than Aβ40,
as is true for intracellular Aβ in other compartments.
Mitochondrial Aβ was first detectable at 4 months of
age, before significant extracellular deposition of Aβ in
this animal model. After 12 months of age, there was
only a slight increase in mitochondrial Aβ at higher
ages.
It was essential to determine if the association of Aβ
with mitochondria could be correlated with functional
perturbations of the organelle [9]. Analysis of mito-
chondria from Tg AβPP mice demonstrated that by 8
months of age, there was a trend towards lower levels
of the respiratory control ratio, compared with nonTg
controls. Furthermore, analysis of respiratory com-
plexes showed reduced complex III and complex IV
activity by 12 months of age in Tg AβPP mitochondria,
versus controls (non-Tg littermates). Although these
data represent correlations, rather than cause-effect re-
lationships, it appears that the presence of mitochon-
drial Aβ is associated with reduced activity of certain
key enzymes in the respiratory chain.
It is important to note that these results raise mul-
tiple questions regarding Aβ and mitochondria: how
does Aβ enter mitochondria? Which mitochondrial
compartments does Aβ reside in? Does Aβ impact on
mitochondrial function? If so, what mechanisms are
involved? Does mitochondrial Aβ affect cellular prop-
erties, such as susceptibility to apoptosis, regulation of
cytosolic calcium or respiratory chain function?
6. Targets of Aβ in mitochondria
The presence of Aβ in mitochondria, taken to-
gether with impaired mitochondrial function, suggests
that amyloid targets vulnerable mitochondrial struc-
tures thereby impacting on overall properties of this
organelle. In view of the known effect of Aβ to desta-
bilize membranes, especially at higher concentrations,
it is certainly possible that nonspecific mechanisms
are responsible for Aβ-induced mitochondrial dysfunc-
tion [78–80]. Pores in the inner mitochondrial mem-
brane would have the capacity to dissipate the proton
motive force which drives ATP production. Another
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Fig. 1. Confocal images from transgenic mice overexpressing mutant AβPP stained for Aβ42 (red) and Hsp60 (green) in the cerebral cortex
(A,C) and hippocampus (B) at 10 months of age (A,B) and nontransgenic littermates (C). Magnification: x 400. Adapted from reference [9].
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Fig. 2. Accumulation of Aβ in mitochondria from transgenic mice overexpressing mutant amyloid precursor protein. ELISA for Aβ42 (A) and
Aβ40 (B) was performed on isolated brain mitochondria from Tg mice of the indicated ages. Adapted from reference [9].
view (complementary or alternative) is that Aβ targets
particular molecules within mitochondria by binding
to them and altering their function. The appeal of this
viewpoint is, depending on the affinity of Aβ for the
target, relatively low concentrations of Aβ could mod-
ulate function of key components of the mitochondrial
regulatory machinery. Such a mechanism could have a
global effect on mitochondrial function.
Using the yeast two-hybrid system, our group iden-
tified ABAD as a short-chain oxidoreductase which
interacted with Aβ and is present in the mitochon-
drial matrix compartment (as well as other intra-
cellular compartments, such as endoplasmic retic-
ulum) [10,81]. ABAD is an enzyme involved in
metabolic homeostasis, particularly in the context of
isoleucine degradation [82–85]. The enzyme methyl-3-
hydroxybutryryl-CoA dehydrogenase (MHBD), which
catabolizes isoleucine and branched-chain fatty acids,
is identical to ABAD. Patients deficient in MHBD/
ABAD display a severe neurologic syndrome, includ-
ing progressive neurodegeneration at a young age [86–
88]. Although the cause of the toxicity is unknown, it
is certainly possible that catabolites in the isoleucine
degradation pathway, such as tiglic acid, accumulate
and exert untoward effects. Drosophila functionally
deficient in ABAD (scully is the Drosophila counter-
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part of ABAD) also have a severe phenotype, namely
developmental lethality, with multiple abnormalities
some of which are reminiscent of defects in fatty acid
oxidation [89]. In this context, ABAD participates
in fatty acid β-oxidation, as well as the metabolism
of β-hydroxybutyrate [82–84]. ABAD shares many
features with other members of the family of short-
chain dehydrogenase reductases, including binding of
an NAD/NADP cofactor and properties of the cat-
alytic site. Its unique properties include participation
in isoleucine degradation, presence in mitochondria (as
well as, to a lesser extent, endoplasmic reticulum in cer-
tain cells), a broad range of substrates, and the ability
to bind Aβ and to facilitate Aβ-induced cell stress [81–
89].
In the context of metabolic homeostasis, overexpres-
sion of ABAD appears to result in a protective pheno-
type [82]. Transgenic mice with targeted overexpres-
sion of ABAD in neurons, using the PDGF B-chain
promoter, were more resistant to ischemic stress. Us-
ing the transient middle cerebral artery model of stroke,
transgenic ABAD mice displayed strokes with reduced
infarct volumes and decreased neurologic deficits. To
our surprise, ABAD transgenic mice had higher base-
line levels of brain ATP, and demonstrated increased
flux of β-hydroxybutyrate through the tricarboxylic
acid cycle, compared with wild-type animals, under
both basal and ischemic conditions. The protective ef-
fects of ABAD in the setting of ischemia could be re-
lated to its metabolic properties (generation of ATP and
enhanced utilization of β-hydroxybutyrate), its direct
effect on mitochondrial properties, or other yet-to-be
discovered mechanisms.
In view of the presence of Aβ and ABAD in mi-
tochondria, as well as the functional importance of
ABAD in homeostasis, it was important to determine
if these two molecules formed a complex in mitochon-
dria. If so, we wanted to assess whether ABAD-Aβ
complex modified the enzymatic properties of ABAD.
Immunoprecipitation studies of AD brain demonstrated
complex formation between ABAD and Aβ in brain
and mitochondrial extracts [10]. This was consistent
with the results of binding studies in which Aβ(1–42),
Aβ(1–40) and Aβ(1–20) demonstrated dose-dependent
saturable binding to ABAD. The C-terminal portion
of Aβ(25–35) did not bind to ABAD, indicating that
ABAD-Aβ interaction was not due to nonspecific in-
teraction with aggregated or fibrillar material. This ob-
servation also suggested the possibility that Aβ might
anchor, via its N-terminus, in ABAD thereby leaving
the C-terminus free and allowing it to multimerize with
additional Aβ. At the level of morphology, both confo-
cal microscopy and immunoelectron microscopy con-
firmed colocalization of ABAD and Aβ in AD brain.
Such morphologic results were relevant, as the bio-
chemical studies clearly reflected observations in dis-
rupted tissue.
The likelihood that ABAD and Aβ interacted in brain
underscored the relevance of determining if there might
be a functional implication of this interaction. First,
we performed studies to attempt to solve the structure
of ABAD-Aβ complex. High resolution crystals were
obtained which demonstrated considerable distortion
of ABAD structure in the presence of Aβ. Specifi-
cally, the NAD cofactor was not bound to ABAD and
there were multiple structural changes in the loops of
ABAD (LD, LE , LF ) whose orientation was important
for ABAD activity. Particularly relevant in this regard
was the observation that the LD loop had disordered
structure in ABAD-Aβ crystals. Comparison of the
LD loop of ABAD with other enzymes in this family
showed an insertion of eleven amino acids, suggesting
the possibility that this might be a site mediating the
binding to Aβ. To test this hypothesis, peptides were
made spanning this region. These studies indicated that
residues 91–119 (including the insertion within the LD
loop) were critical for Aβ binding to ABAD.
The relevance of ABAD for promoting Aβ-induced
cell stress was demonstrated in studies with trans-
genic mice overexpressing AβPP and ABAD in neu-
rons [10]. These double transgenic animals displayed
increased generation of reactive oxygen species in
the brain, by electron paramagnetic resonance spec-
troscopy, and accelerated impairment of spatial learn-
ing/memory (Fig. 3A–B). Cultured neurons from these
double transgenic mice showed spontaneous release of
reactive oxygen species (the defect resulting in oxy-
gen free radical production appears to occur at complex
III) [90] and cytochrome c from mitochondria [10,90].
In fact, neurons cultured from these animals displayed
spontaneous apoptosis. Although the precise mech-
anisms through which ABAD perturbs mitochondrial
functions remain to be determined, it is clear that in
model systems ABAD-Aβ interaction modulates prop-
erties of ABAD. Using purified proteins, addition of Aβ
to ABAD decreased the enzyme’s activity to a broad
range of substrates. In vivo, a much more complex set
of interactions appears to occur that stimulates forma-
tion of reactive oxygen species and other events.
In addition to ABAD, Aβ is likely to interact with
components of the mitochondrial import machinery
(assuming that Aβ is produced outside mitochondria
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Fig. 3. Panel A. Generation (by EPR spectroscopy) of free radicals in brains of double transgenic mice overexpressing mutant amyloid precursor
protein and ABAD under control of the PDGF B chain promoter. Note that the amplitude of the spectra for Tg mutant(m)AβPP, Tg ABAD
and non-Tg animals has been increased ten-fold to display spectra which showed only low-level changes compared with the double transgenics
(mAβPP/ABAD). Panel B displays spatial learning in 4.5–5 month-old double transgenic mice (compared with other groups) tested in the
radial-arm water maze. Adapted from reference [10].
and imported into the organelle; see above) and mito-
chondrial chaperones. In the latter case, Aβ has been
shown to bind HSP70 and HSP16 family members,
based on immunoprecipitation assays in a transgenic C.
elegans system [91]. Another apparently specific Aβ-
interacting protein is HtrA2/Omi [11], a serine protease
with proapoptotic properties [92–96]. It serves as a
binding protein for inhibitor of apoptosis protein (IAP).
HtrA2/Omi is imported into mitochondria via a mi-
tochondrial targeting sequence which is subsequently
autocatalytically removed after entering the organelle.
Apoptotic stimuli cause release of HtrA2/Omi from
mitochondria, which then binds to IAPs [92–96]. Al-
though the functional significance of the interaction of
Aβ with HtrA2/Omi is unclear, in terms of its impact on
programmed cell death, it is possible that modulation
of HtrA2/Omi activity occurs.
7. Hypothesis
The observations cited in this review highlight a
relationship between altered mitochondrial function,
Aβ and Alzheimer’s disease. While it is not possi-
ble to draw conclusions as to which comes first and
whether mitochondrial perturbation is pathogenic in
AD, it is clear that mitochondrial dysfunction is asso-
ciated with AD. We propose that impaired mitochon-
drial function, at the level of complexes III and/or IV,
promotes leakage of electrons resulting in generation
of reactive oxygen species. Such free radicals perturb
cellular and mitochondrial properties further derang-
ing neuronal/microglial properties. However, there are
many possibilities for mechanisms underlying such mi-
tochondrial dysfunction. For example, the interaction
of extracellular Aβ with membrane receptors, such as
RAGE, could trigger activation of NADPH oxidase re-
sulting in free radical formation. Alternatively, or in
addition, intrinsic defects in complex IV (nitric oxide
also decreases function of complex IV) would tend to
cause accumulation of reduced components of the elec-
tron transport chain, promoting the possibility of elec-
tron leakage. Mutations in mitochondrial DNA, es-
pecially those in the control region, which would im-
pact on transcription of genes essential for mitochon-
drial function could also affect the integrity of cellular
respiration. The presence of Aβ within mitochondria
provides another level of complexity in this setting, as
mitochondrial Aβ could seek out particular molecular
targets, such as ABAD or HtrA2/Omi. Alternatively,
changes in mitochondrial properties in AD could be in-
direct, potentially due to increased generation of nitric
oxide and other changes related to signal transduction
mechanisms in the cytosol. Further analysis of mito-
chondrial properties in AD will be necessary to dissect
this situation and understand if mitochondrial pertur-
bation is pathogenic in this neurodegenerative disease.
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